Item 5.07 Submission of Matters to a Vote of Security Holders. On August 4, 2022, Avadel Pharmaceuticals plc (the “Company”) held its 2022 Annual Meeting of Shareholders (the “Annual Meeting”). Proxies were solicited pursuant to the Company’s definitive proxy statement filed on April 29, 2022, as amended on June 15, 2022 (the “Proxy Statement”), with the Securities and Exchange Commission (the “Commission”) under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares, par value $0.01 per share, of the Company (the “Ordinary Shares”) entitled to vote at the Annual Meeting was 59,038,237. The number of Ordinary Shares present or represented by valid pro(…)